Search

everythinglearnresearchcommunity

for

Search:↓

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Trichohyalin in hair can trigger immune attacks in alopecia areata.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Blocking LFA-1 prevents hair loss in mice.

Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Patients with thyroid disorders show different symptoms and antibody levels.

HTLV-1-associated lichenoid dermatitis (HALD) is linked to an immune response against HTLV-1-infected cells.

CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.

High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.

pCLCA2 protein may help maintain skin structure and function.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

People with atopic dermatitis have more CD4+ T cells that respond to a certain bacterial lipid, which may play a role in the skin condition's inflammation.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Four antibodies were developed to help study hair follicle cell differentiation.

TLR4 is important in aging-related diseases and could be a new treatment target.

Dual TCR Treg cells are common in mouse tissues and vary by location.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.

Clonally expanded CD8+ T cells cause alopecia areata.

CD3+ T-cell presence is a reliable marker to tell apart alopecia areata from pattern hair loss.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Tph cells are linked to the severity of systemic lupus erythematosus.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.